Hypertension Pharmacotherapy: A Practical Approach

Similar documents
Managing Hypertension in 2016

Preventing and Treating High Blood Pressure

Modern Management of Hypertension

Modern Management of Hypertension: Where Do We Draw the Line?

Hypertension Update Clinical Controversies Regarding Age and Race

ADVANCES IN MANAGEMENT OF HYPERTENSION

Hypertension Update 2009

ADVANCES IN MANAGEMENT OF HYPERTENSION

Jared Moore, MD, FACP

Objectives. Describe results and implications of recent landmark hypertension trials

Treating Hypertension in Individuals with Diabetes

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Hypertension Management Controversies in the Elderly Patient

Hypertension (JNC-8)

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

Hypertension Management: A Moving Target

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Combination Therapy for Hypertension

The Latest Generation of Clinical

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Hypertension 2015: Recent Evidence that Will Change Your Practice

Management of High Blood Pressure in Adults

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

Hypertension and Cardiovascular Disease

Masked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre

Update in Hypertension

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Difficult to Treat Hypertension

2014 HYPERTENSION GUIDELINES

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Diagnosis and treatment of hypertension. Kari Nelson, MD MSHS Division of General Internal Medicine VA Puget Sound, University of Washington

Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets

Conflict of Interest Disclosure

Hypertension in the very old. Objectives: Clinical Perspective

Adult Blood Pressure Clinician Guide June 2018

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Management of Hypertension in Women

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Individual management of arterial hypertension. Doumas Michael, Internist Lecturer, Aristotle University, Thessaloniki

Egyptian Hypertension Guidelines

Pharmacologic Management of Hypertension

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

STANDARD treatment algorithm mmHg

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

DEPARTMENT OF GENERAL MEDICINE WELCOMES

How to approach resistant hypertension. Teh-Li Huo, M.D., Ph.D.

Network Hypertension Algorithm

Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN

Hypertension: Update

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

By Prof. Khaled El-Rabat

What in the World is Functional Medicine?

Getting BP to goal: Virginia L. Hood MB.BS, MPH, FACP

Brent M. Egan, MD Professor of Medicine USCSOM Greenville

Hypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center

Approach to patient with hypertension. Dr. Amitesh Aggarwal

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Drug-Induced Diabetes May Not Be Harmful But Should Be Prevented. Jeffrey A. Cutler, MD, MPH

The State of Hypertension in NZ in 2010 personal view

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

Updates in Cardiovascular Recommendations for Diabetic Patients

First line treatment of primary hypertension

Systolic Blood Pressure Intervention Trial (SPRINT)

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Audience Response. Hypertension. Case: Mr. J. Measuring BP. Non-pharmacologic intervention. Case: Mr. J. Session ID: HTN411

Hypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly

Management of Difficult or Resistant Hypertension in General Practice

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

Transcription:

Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center

1. 2. JNC 8 Relaxed drug Rx thresholds Office BP My Approach Pull the trigger on drug Rx Out-of-office BP 3. Higher drug doses as in RCTs Low-dose combination drug Rx

Daytime BP >135/85 Sleep BP > 125/75 MY APPROACH Initiate or intensify drug therapy if: Less intensive therapy for frail elderly More intensive therapy for high risk patients First-line combination drug therapy CCB plus ARB Add-on therapy Thiazide Aldosterone antagonist Vasodilating β-blocker Hypertension Center

Case #1: 79 y/o woman with no h/o CVD but family h/o stroke Healthy, robust, BMI 24 Office BP 200/85 mmhg Her home systolic BPs 132-149 Normal electrolytes, Cr 0.7 No diabetes, normal lipids No current medication Should we prescribe BP medication?

Relaxed Drug Therapy BP Thresholds JNC 8 (2014) JNC 7 (2003) Age > 60 Age < 60 Diabetes, CKD 150/90 140/90 140/90 140/90 130/80

Older Patients Evidence for Office SBP < 150 200 Systolic BP, mmhg 190 180 170 160 150 140 130 HYVET SCOPE SHEP SystEur Syst-China C & W STOP RCTs (1995-2008) Drug vs. placebo - HYVET: age 80+ - Others: ages 65-79 - Not designed to test different thresholds or goals of Rx 120 Initial Final STOP2

Hypertensive Patients in General Evidence for Office SBP < 140 Systolic BP, mmhg 180 170 160 150 140 130 120 Initial Final FEVER ELSA NORDIL CAPP CONVINCE VALUE ASCOT ACCOMPLISH ALLHAT ALLHAT2 ONTARGET LIFE INVEST (ECG-LVH) (CAD) RCTs (1995-2008) new vs. old drugs - Mean age 67 years - No data < age 50 - Not designed to test benefits of more vs. less intensive Rx

Systolic BP (mm Hg) 136 121 Standard Rx Intensive Rx Years

CVD Event Death Years

Subgroup Hazard Ratio, 95% CI Our Patient Elderly- 33% Woman- 16%% Untreated home SBP 132-149 24-30% Intensive Rx Better Standard Rx Better

Risks of more intensive Rx? (+) (-) No increase in: Injurious falls Symptomatic orthostatic hypotension Overall SAEs Increase in: Hyponatremia +76% Hypokalemia +50% Acute kidney injury +71%

1. 2. JNC 8 Relaxed drug Rx thresholds Office BP My Approach Pull the trigger on drug Rx Out-of-office BP 3. Higher drug doses as in RCTs Low-dose combination drug Rx

Pull the trigger on drug Rx? Blood pressure, mm Hg 250 200 150 100 50 0 15:00 24:00 Office visits sleep 15:00 Robust 79 y/o woman with: Stage 1 ISH (awake) White Coat Rkn Nocturnal HTN- SBP 142 (normal sleep BP < 120/70) Rx: Amlodipine 2.5 mg QHS Next, losartan 25 mg QHS Start low, go slow Avoid orthostatic BP

Blood pressure, mmhg Frail 69 y/o woman with on-treatment office SBP 160 Hour: lunch White coat reaction breakfast lunch bathroom ISH & white coat HTN Postprandial & orthostatic hypotension Less intensive Rx

1. 2. JNC 8 Relaxed drug Rx thresholds Office BP My Approach Pull the trigger on drug Rx Out-of-office BP 3. Higher drug doses as in RCTs Low-dose combination drug Rx

Case #2: 61 y/o woman with severe hypertension and palpitations BMI 29, OWNL exam Normal: CBC, lipids Normal ECG Normal 126! CBC 4.3 116 Normal 101 lipids 29 0.9 14

Her Initial Rx 1. Losartan HCT (Hyzaar) 100-25 QD 2. Lisinopril 40 mg QD 3. Atenolol 50 mg QD 4. KCL 20meq BID 5. Clonidine 0.2 mg BID plus 0.1 mg PRN BP >180/110 How to address: a) medication regimen? b) hyponatremia? c) secondary HTN?

BP reduction 1.25 mg indapamide =25 mg chlorthalidone = 60 mg HCTZ Similar metabolic side-effects

Incidence per 100,00 person-years Women 60 y/o Men

Hyponatremia-Associated Symptoms

Monotherapy dose escalation BP Reduction Side- Effects Dose

Combining drugs from different classes is 5 times more effective lowering BP than doubling the dose of one drug.

Three 1 st Line Drug Classes for Hypertension in 2016 Thiazide diuretics Calcium channel blockers (CCBs) Renin angiotensin system blockers ACEI or ARB

Discontinuation rates at 1 year: Worst with thiazides: 75% Intermediate with CCBs, ACEIs: 48% Best with ARBs: 35%

Resistant (Difficult) HTN Office BP > 140/90 x 3 drugs Pseudo-Resistant White coat HTN Medication regimen Patient non-compliance Interfering meds (NSAIDs) Truly Resistant Secondary HTN adrenal (aldo, pheo) renal, renovascular Difficult primary HTN Aldosterone antagonist

Subclinical 1972

Initial Rx 1. HCTZ 2. KCl 3. Losartan 4. Lisinopril 4. Atenolol 5. Clonidine (+PRN dosing) Na, K ARB plus ACEI increases risk of AKI No stroke protection Rebound BP surges

New Rx 1. Amlodipine 5 mg (CCB) 2. Telmisartan 80 mg (ARB) 3. Coreg CR 40 mg (vasodilating BB)- add on 1 st line Office SBP much better but Normal spells 143 at CBC 4.2 home with 69 SBP Normal >200. Plasma 102 lipids 29 metanephrines normal. 16 0.8

Spells with Palpitations New Regimen Averages Day: 131/79 Night: 114/67

EPS: Atrial tachycardia

Final Rx Hypertension Amlodipine 5 mg Telmisartan 80 mg Atrial Tachycardia Metoprolol 100 mg Diltiazem 360 mg

Daytime BP >135/85 Sleep BP > 125/75 MY APPROACH Initiate or intensify drug therapy if: Less intensive therapy for frail elderly More intensive therapy for high risk patients First-line combination drug therapy CCB plus ARB Add-on therapy Thiazide Aldosterone antagonist Vasodilating β-blocker Hypertension Center